Adynxx (FRA:HL1C) Inventories, Other : €0.00 Mil (As of Sep. 2019)

View and export this data going back to 1998. Start your Free Trial

What is Adynxx Inventories, Other?

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. Adynxx's other inventories for the quarter that ended in Sep. 2019 was €0.00 Mil.

Adynxx's quarterly other inventories declined from Mar. 2019 (€0.10 Mil) to Jun. 2019 (€0.00 Mil) but then stayed the same from Jun. 2019 (€0.00 Mil) to Sep. 2019 (€0.00 Mil).

Adynxx Inventories, Other Historical Data

The historical data trend for Adynxx's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adynxx Inventories, Other Chart

Adynxx Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Inventories, Other

Get a 7-Day Free Trial

Adynxx Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Inventories, Other	Get a 7-Day Free Trial															-	-	0.10	-	-

Adynxx Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.

Adynxx (FRA:HL1C) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adynxx Inc (FRA:HL1C) » Definitions » Inventories, Other

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Pine Street, Suite 500, San Francisco, CA, USA, 94111

Website

http://www.adynxx.com

Adynxx Inc is a United States-based clinical-stage biopharmaceutical company. It is focused on the development of a new class of therapeutics called transcription factor decoys and bringing to the market novel, disease-modifying products to address unmet needs in the treatment of pain and inflammation. Its pipeline includes brivoligide, a Phase 2 drug candidate intended to address postoperative pain, and AYX2, a pre-clinical candidate intended to treat chronic syndromes of pain, including both inflammatory and neuropathic pain.

Adynxx (FRA:HL1C) Headlines

No Headlines